AstraZeneca PLC and Daiichi Sankyo Co., Ltd. teased the possibility that the Phase III DESTINY-Breast04 study testing Enhertu (trastuzumab deruxtecan) in individuals with breast cancer categorized as HER-2 low was potentially paradigm-changing months ago with the release of top-line data, and the level of benefit seen in the full data presented at the American Society of Clinical Oncology (ASCO) meeting on 5 June clinched it.
The data are poised to change the way doctors think about categorizing breast cancer nearly 25 years after Genentech, Inc. launched the first HER2-targeted drug for breast cancer, Herceptin (trastuzumab)